Eli Lilly and Company
LLY
$989.87
$22.882.37%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 25.28B | 20.64B | 18.41B | 13.80B | 11.11B |
| Total Depreciation and Amortization | 2.04B | 2.00B | 1.90B | 1.89B | 1.83B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -446.70M | 2.27B | 2.40B | 3.11B | 3.38B |
| Change in Net Operating Assets | -6.39B | -8.09B | -6.64B | -7.86B | -7.00B |
| Cash from Operations | 20.48B | 16.81B | 16.06B | 10.94B | 9.32B |
| Capital Expenditure | -8.66B | -7.84B | -6.79B | -6.05B | -5.58B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.72B | -661.00M | -549.70M | -300.00K | -948.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.16B | -2.47B | -2.75B | -5.06B | -4.95B |
| Cash from Investing | -11.54B | -10.97B | -10.09B | -11.11B | -11.48B |
| Total Debt Issued | 8.48B | 13.17B | 13.17B | 11.43B | 11.43B |
| Total Debt Repaid | -4.02B | -5.12B | -2.07B | -1.07B | 839.80M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -5.26B | -4.11B | -4.65B | -4.39B | -3.70B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -5.59B | -5.38B | -5.21B | -5.03B | -4.86B |
| Other Financing Activities | -676.70M | -771.70M | -792.50M | -809.60M | -787.20M |
| Cash from Financing | -7.06B | -2.21B | 440.60M | 120.90M | 2.92B |
| Foreign Exchange rate Adjustments | 307.10M | 372.10M | 10.40M | 205.60M | -129.50M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.19B | 4.00B | 6.42B | 151.60M | 632.40M |